Neuroscience
Meta-Analysis
100%
Dementia Praecox
94%
Major Depressive Disorder
82%
Typical Antipsychotic
36%
Mood Disorder
26%
Placebo
26%
Receptor Gene
25%
Randomized Controlled Trial
22%
Brain-Derived Neurotrophic Factor
21%
Bipolar Disorder
20%
Methamphetamine-Induced Psychosis
18%
Antidepressant
16%
Antipsychotic
15%
Haplotype
15%
Aripiprazole
14%
Negative Syndrome
13%
Fluvoxamine
13%
Bipolar Depression
12%
5-HT6 Receptor
12%
Selective Serotonin Reuptake Inhibitor
11%
Positive Syndrome
11%
Risperidone
11%
Dorsolateral Prefrontal Cortex
11%
Olanzapine
10%
Quetiapine
9%
Alzheimer's Disease
9%
5-HT1A Receptor
9%
Nuclear Receptor NR1D1
9%
Memantine
9%
Lurasidone
9%
Treatment of Schizophrenia
8%
Cognitive Function
7%
CHRNA4
6%
Suvorexant
6%
Hamilton Rating Scale for Depression
6%
Startle Response
6%
Prokineticin
6%
Nuclear Receptor
6%
Catecholamine
6%
Circadian Rhythm
6%
Haloperidol
6%
Voxel-Based Morphometry
6%
DNA Polymorphism
6%
Neu Differentiation Factor
6%
Factor X
6%
Lewy Body
6%
Methyltransferase
6%
Psychosis
5%
Mirtazapine
5%
Depression
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
51%
Typical Antipsychotic
33%
Antipsychotic
33%
Randomized Controlled Trial
30%
Adverse Event
29%
Aripiprazole
26%
Major Depression
22%
Negative Syndrome
18%
Alzheimer's Disease
18%
Disease
18%
Blonanserin
18%
Olanzapine
15%
Quetiapine
15%
Memantine
15%
Bipolar Depression
15%
Remission
14%
Risperidone
14%
Positive Syndrome
14%
Lurasidone
13%
Symptom
11%
Paliperidone
11%
Recurrence Risk
10%
Brexpiprazole
10%
Tolerability
8%
Perospirone
8%
Random Effects Model
7%
Bipolar Disorder
7%
Headache
7%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
7%
Clozapine
6%
Delirium
6%
Yokukansan
6%
Add on Therapy
6%
Akathisia
5%
Psychosis
5%
Monotherapy
5%
Depression
5%
Somnolence
5%
Cognitive Defect
5%
Keyphrases
Meta-analysis
40%
Major Depressive Disorder
34%
Systematic Meta-analysis
24%
Japanese Population
16%
Gene Disorders
12%
Schizophrenia
12%
Network Meta-analysis
9%
Confidence Interval
9%
Brain-derived Neurotrophic Factor
9%
Alzheimer's Disease
9%
Intermittent theta Burst Stimulation (iTBS)
9%
Lurasidone
9%
Randomized Placebo-controlled Trial
8%
Non-associated
7%
Adverse Events
7%
Standardized Mean Difference
7%
Risk Ratio
7%
Association Study
7%
Bipolar Depression
6%
Mood Disorders
6%
HF-rTMS
6%
Aripiprazole
6%
Bipolar Disorder
6%
Serotonin 6 Receptor
6%
Serotonin-1A Receptor
6%
Protease-activated Receptor 4 (PAR4)
6%
Receptor Gene
6%
Aripiprazole Once-monthly
6%
Translin
6%
X Gene
6%
SIRT1 Gene
6%
Methamphetamine-induced Psychosis
6%
Memantine
6%
Meta-analysis of Randomized Controlled Trials
6%
Treatment-resistant Depressive Disorder
6%
Newer Antidepressants
6%
Placebo
5%
Genotype
5%
Pathophysiology
5%
Antidepressants
5%
Left DLPFC
5%
